| 122.77 3.59 (3.01%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 151.99 | 1-year : | 177.52 |
| Resists | First : | 130.13 | Second : | 151.99 |
| Pivot price | 116.84  |
|||
| Supports | First : | 116.09 | Second : | 107.41 |
| MAs | MA(5) : | 118.02 |
MA(20) : | 117.52 |
| MA(100) : | 109.65 |
MA(250) : | 59.43 |
|
| MACD | MACD : | -0.9 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 71.3 |
D(3) : | 59.7 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 148.83 | Low : | 4.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABVX ] has closed below upper band by 16.0%. Bollinger Bands are 25.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 123.51 - 124.1 | 124.1 - 124.65 |
| Low: | 114.5 - 115.15 | 115.15 - 115.76 |
| Close: | 121.66 - 122.72 | 122.72 - 123.72 |
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Sun, 08 Feb 2026
Abivax SA reports increased losses in Q3 2025 amid rising R&D costs - MSN
Sun, 08 Feb 2026
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sat, 07 Feb 2026
Behavioral Patterns of ABVX and Institutional Flows - Stock Traders Daily
Fri, 06 Feb 2026
Abivax SA (ABVX) Stock Analysis: Eyeing a 37.93% Potential Upside, All Eyes on Phase 3 Trials - DirectorsTalk Interviews
Mon, 02 Feb 2026
Federated Hermes Inc. Makes New Investment in Abivax SA Sponsored ADR $ABVX - MarketBeat
Mon, 26 Jan 2026
Merger Arbs See Wide-Open Deal Window With Biotech Top of List - Bloomberg.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 5.179e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 2,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1795e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 630.8 % |
| Return on Equity (ttm) | -31.7 % |
| Qtrly Rev. Growth | 5.31e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -171 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.9 |
| Dividend | 0 |
| Forward Dividend | 3.08e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|